SAMHD1 is a barrier to antimetabolite-based cancer therapies.

JSON

Rudd SG, Schaller T, Herold N

Mol Cell Oncol 4 (2) e1287554 [2017-02-03; online 2017-02-03]

The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies.

PubMed 28401188

DOI 10.1080/23723556.2017.1287554

Crossref 10.1080/23723556.2017.1287554

pmc: PMC5383367
pii: 1287554